Rein Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 21.53K shares, a 83.31% decline from fiscal 2024.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 129.00K shares.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 113.04K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 21.53K shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 21.60K shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 62.46K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 21.53K shares 10-Q · filed 2025-05-15 | 150.53K shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | 71.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | 129.00K shares 10-K · filed 2025-04-07 |
| 2024-09-30 | 40.86K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 128.92K shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | 88.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 88.07K shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-15 | 0.00 shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | 0.00 shares 10-K · filed 2025-04-07 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-13 | 1.04K shares derived: sum of 4 quarters · filed 2023-10-13 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 45.68K shares derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-08 | |
| 2021-12-31 | 1.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 113.04K shares 10-K · filed 2022-03-28 |
| 2021-09-30 | 44.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | 126.56K shares 10-K · filed 2020-03-30 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 137.63K shares derived: sum of 4 quarters · filed 2019-11-07 |
| 2019-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | 137.63K shares derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | 126.56K shares 10-Q · filed 2019-05-08 | 140.65K shares derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | 11.07K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | 24.66K shares 10-K · filed 2019-03-29 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | 18.61K shares derived: sum of 4 quarters · filed 2018-11-07 |
| 2018-06-30 | 3.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 26.69K shares derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | 10.56K shares 10-Q · filed 2018-05-09 | |
| 2017-12-31 | 5.03K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | 31.63K shares 10-K · filed 2018-04-02 |
| 2017-09-30 | 8.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |